Table 1.
Summarizing clinical demographics for participants in all groups.
| Controls | PET/CT | ACS phenotype | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AP | NSTEMI | STEMI | ||||||||
| N | 62 | 100 | 47 | 48 | 117 | |||||
| Male, N (%) | 36 | (58) | 44 | (44) | 38 | (81) | 40 | (83) | 104 | (89) |
| Age, years | 39 | [27-47] | 50 | [41–58] | 57 | [49–64] | 57 | [48–61] | 52 | [41–58] |
| Never smoking, N (%) | – | 44 | (44) | 1 | (2) | 7 | (15) | 17 | (15) | |
| Chest pain, hours | – | – | 5.8 | [1.8–20.0] | 5.8 | [2.4–34.3] | 3.7 | [2.9–9.0] | ||
| ≤ 2 h pain, N (%) | – | – | 14 | (30) | 10 | (21) | 16 | (14) | ||
| >2 h pain, N (%) | – | – | 32 | (70) | 35 | (79) | 98 | (86) | ||
| Hypertension, N (%) | – | 31 | (31) | 9 | (19) | 25 | (52) | 65 | (56) | |
| Diabetes, N (%) | – | 3 | (3) | 6 | (13) | 10 | (21) | 11 | (9) | |
| Hyperlipidemia, N (%) | – | 13 | (13) | 4 | (9) | 29 | (60) | 52 | (44) | |
| Prev MI, N (%) | – | 5 | (5) | 19 | (40) | 8 | (17) | 15 | (13) | |
| 1-year survival, N (%) | – | – | 46 | (98) | 47 | (98) | 110 | (94) | ||
| Anti-β1AR Ab μg/ml | 1.08 | [0.78–1.48] | 1.06 | [0.83–1.43] | 0.76 | [0.57–0.93] | 0.76 | [0.61–1.11] | 0.71 | [0.50–0.91] |
| Trop-T, ng/l | 6.7 | [4.2–15.9] | 80.2 | [23.5–503.5] | 133.3 | [39.1–710.9] | ||||
| CKmax, U/l | 84 | [68–152] | 185 | [94–391] | 311 | [150–777] | ||||
| NT-BNP, ng/l | 142.3 | [55.8–260.0] | 251.0 | [74.2–251.0] | 118.5 | [56.5–540.2] | ||||
| GDF-15 pg/ml | 1369 | [875–2094] | 1399 | [1141–1737] | 1497 | [1142–2130] | ||||
| hsCRP, mg/l | 1.79 | [0.49–4.98] | 2.63 | [0.86–6.13] | 2.28 | [0.99–7–89] | ||||
Values are median [interquartile range] unless otherwise stated. All clinical variables demonstrated a highly significant difference (p < 0.001) across groups when tested using Kruskal-Wallis H-test. Controls were excluded from risk factor comparisons. Regarding ß1adrRab concentrations, these are compared in detail in Figure 1. ACS, acute coronary syndrome; PET/CT, positron emission tomography; AP, angina pectoris; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST elevation myocardial infarction; Prev MI, previous myocardial infarction; anti-β1AR Ab, ßeta1 adrenergic receptor antibody; Trop-T, Troponin-T (laboratory reference value ≤ 15 ng/l); CKmax, maximum creatinine kinase (laboratory reference value ≤ 168 U/l); B-NP, B naturetic peptide (laboratory reference value ≤ 146 ng/l); GDF-15, Growth differentiation factor; hsCRP, high-sensitivity C-reactive protein (laboratory reference value < 0.5 mg/l).